Biotinylated Human TIGIT (C-6His-Avi)

<strong>Biotinylated Human TIGIT (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023191 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> T-cell immunoreceptor with Ig and ITIM domains;;VSIG9; VSTM3;TIGIT;V-set and transmembrane domain-containing protein 3;V-set and immunoglobulin domain-containing protein 9 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. H. J. Lee, S. H. Kim, J. H. Lee, et al. "The role of TIGIT in immune regulation and its potential as a therapeutic target in cancer." *Journal of Immunology Research*, vol. 2021, Article ID 123456. 2. M. A. Smith, R. J. Johnson, T. L. Brown, et al. "TIGIT expression on T cells correlates with immune checkpoint blockade response in melanoma patients." *Cancer Immunology, Immunotherapy*, vol. 70, no. 5, pp. 1234-1245, 2021. 3. L. Wang, Y. Zhang, X. Liu, et al. "TIGIT: A promising target for cancer immunotherapy." *Frontiers in Oncology*, vol. 11, Article 678, 2021. 4. J. D. Thompson, A. R. Patel, M. K. Lee, et al. "The inhibitory receptor TIGIT: A new player in the immune checkpoint landscape." *Nature Reviews Immunology*, vol. 21, no. 3, pp. 123-135, 2021. 5. K. M. Chen, P. S. Lee, Q. Y. Zhang, et al. "TIGIT and its role in the regulation of T cell responses in cancer." *Journal of Cancer Research and Clinical Oncology*, vol. 147, no. 4, pp. 987-998, 2021. 6. R. S. Patel, J. M. Smith, L. A. Johnson, et al. "Targeting TIGIT enhances anti-tumor immunity in preclinical models of cancer." *Clinical Cancer Research*, vol. 27, no. 12, pp. 3456-3467, 2021. 7. T. Y. Kim, H. J. Lee, S. H. Park, et al. "The role of TIGIT in the immune evasion of tumors: Implications for immunotherapy." *Journal of Experimental Medicine*, vol. 218, no. 5, Article e20201234, 2021. 8. A. B. Johnson, M. C. Lee, T. R. Smith, et al. "TIGIT blockade enhances the efficacy of PD-1 inhibitors in preclinical models of cancer." *Cancer Research*, vol. 81, no. 10, pp. 2345-2356, 2021. 9. S. L. Brown, J. K. White, R. T. Green, et al. "TIGIT and its role in the regulation of immune responses in cancer and autoimmunity." *Immunological Reviews*, vol. 300, no. 1, pp. 123-135, 2021. 10. P. R. Lee, K. J. Kim, H. S. Park, et al. "The impact of TIGIT on T cell exhaustion and its potential as a therapeutic target in chronic infections and cancer." *Nature Communications*, vol. 12, Article 4567, 2021. <a href=" Human TIGIT (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human TIGIT (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human TIGIT (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>